EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

Launched by CASE COMPREHENSIVE CANCER CENTER · Feb 8, 2024

Keywords

ClinConnect Summary

The EQUITY GI clinical trial is designed to improve the care of Black patients diagnosed with various types of gastrointestinal (GI) cancers, such as colon, rectal, pancreatic, and stomach cancer. The study aims to enhance the quality of treatment by ensuring proper testing for specific markers in the tumor or blood that can guide treatment decisions. Participants will receive standard care and have the opportunity to learn about and enroll in clinical trials that may be suitable for them. Additionally, the study team will provide educational materials to help participants better understand their condition and treatment options.

To be eligible for this trial, participants must be at least 18 years old and newly diagnosed with a GI cancer. There are no additional restrictions, so anyone who fits this description can consider joining. Throughout the study, participants can expect to receive support from the research team, including assistance with understanding their diagnosis and treatment, as well as help with clinical trial enrollment if they choose. This study is important for promoting inclusivity and improving healthcare outcomes for Black patients with GI cancers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult ≥ 18 years old.
• • 2. Newly diagnosed Black GI cancer participants irrespective of stage. Eligible tumor types include anal carcinoma, rectal cancer, colon cancer, small bowel cancer, appendix carcinoma, hepatobiliary cancer, pancreatic cancer, gastroesophageal cancer, gastrointestinal neuroendocrine tumors, and gastrointestinal stromal tumor.
• • 3. Patient able and willing to comply with study procedures
• • 4. The patient is able to understand and willing to sign and date the written informed consent form at the screening visit.
• Exclusion Criteria:
• • NONE